Articles

Bacterial Expression of TMTP1-Fused L-Asparaginase for Targeting Leukemia and Metastatic Tumor Cells

Abstract

L-asparaginase is recognized as a first-line anticancer drug for acute lymphoblastic leukemia (ALL); however, low-substrate specificity and exhibiting glutaminase activity cause various off-target toxicities on normal cells. In the following study, we functionalized wild-type asparaginase with the TMTP1 targeting peptide which specifically targets a variety of hematological and metastatic cancer cells. The peptide sequence was genetically added to the N-terminal end of the asparaginase using the restriction endonuclease-free cloning method. Wild-type and engineered asparaginases were expressed in E. coli and purified by Nickel affinity chromatography column. The in vitro activity of both types of enzymes was evaluated by Nessler’s method. The sequencing results showed that the TMTP1 sequence was added in the correct frame to the asparaginase. Wild-type and TMTP1-fused asparaginases were produced in a soluble state with the specific activity of 172 U/mg and 153 U/mg, respectively. The evidence from this study suggests that TMTP1-fused asparaginase could preserve its solubility and activity compared to the wild-type species and can be proposed for future research in anticancer therapies.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
2. Liu YQ, Wang XL, He DH, Cheng YX. Protection against chemotherapy-and radiotherapy-induced side effects: A review based on the mechanisms and therapeutic opportunities of phytochemicals. Phytomedicine 2021;80:153402.
3. Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans 2018;47:6645-53.
4. Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: Current perspectives and new challenges. Ecancermedicalscience 2019;13:961.
5. Cooper BM, Iegre J, O’Donovan DH, Halvarsson MÖ, Spring DR. Peptides as a platform for targeted therapeutics for cancer: Peptide–drug conjugates (PDCs). Chem Soc Rev 2021;50:1480-94.
6. Administration USF and D. Impact story: developing the tools to evaluate complex drug products: peptides. FDA (Accessed 02 February, 2019, at https://www fda gov/Drugs/ScienceResearch/ucm578111 htm. 2019 .)
7. Araste F, Abnous K, Hashemi M, Taghdisi SM, Ramezani M, Alibolandi M. Peptide-based targeted therapeutics: Focus on cancer treatment. J Control Release 2018;292:141-62.
8. Administration F and D, approves lutetium Lu FDA. 177 dotatate for treatment of GEP-NETS. (Accessed 26 January, 2018, at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets.)
9. Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, Marini B. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma 2018;59:1797-806.
10. Vimal A, Kumar A. Biotechnological production and practical application of L-asparaginase enzyme. Biotechnol Genet Eng Rev 2017;33:40-61.
11. Chand S, Mahajan RV, Prasad JP, Sahoo DK, Mihooliya KN, Dhar MS, et al. A comprehensive review on microbial l‐asparaginase: Bioprocessing, characterization, and industrial applications. Biotechnol Appl Biochem 2020;67:619-47.
12. Xiao M, Hong Z, Sun L, Wu Y, Zhang N, Liu Y, et al. TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases. J Huazhong Univ Sci Technolog Med Sci 2011;31:608.
13. Yang W, Luo D, Wang S, Wang R, Chen R, Liu Y, et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res 2008;14:5494-502.
14. Wriston Jr JC. Asparaginase. Methods Enzymol 1985;113:608-18.
15. Gunnars B, Nygren P, Glimelius B. Assessment of quality of life during chemotherapy. Acta Oncol 2001;40:175-84.
16. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, et al. L‐asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011;117:238-49.
17. Wriston JC, Yellin TO. L-asparaginase: a review. Adv Enzymol Relat Areas Mol Biol 1973;39:185-248.
18. Cachumba JJM, Antunes FAF, Peres GFD, Brumano LP, Santos JC dos, Silva SS da. Current applications and different approaches for microbial L-asparaginase production. Braz J Microbiol 2016;47:77-85.
19. van den Ent F, Löwe J. RF cloning: a restriction-free method for inserting target genes into plasmids. J Biochem Biophys Methods 2006;67:67-74.
20. Guo L, Wang J, Qian S, Yan X, Chen R, Meng G. Construction and structural modeling of a single‐chain Fv–asparaginase fusion protein resistant to proteolysis. Biotechnol Bioeng 2000;70:456-63.
Files
IssueVol 61 No 4 (2023) QRcode
SectionArticles
DOI https://doi.org/10.18502/acta.v61i4.13173
Keywords
L-asparaginase TMTP1 targeting peptide Acute lymphoblastic leukemia Restriction endonuclease-free cloning
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Kheirandish MH, Tollabi M, Davami F, Rahmani B, Hashemi Aval NS, Behroozi J, Zarei Jaliani H. Bacterial Expression of TMTP1-Fused L-Asparaginase for Targeting Leukemia and Metastatic Tumor Cells. Acta Med Iran. 2023;61(4):223-228.